Blog and News
BlogUnlocking cancer insights: SomaLogic-EPIC study partnership reveals how lifestyle choices impact risk
Having provided more insights into the relationship between environmental factors and the incidence of cancer than any other cohort in existence, EPIC has been crucial to understanding how lifestyle influences risk of disease. This is important because current cancer research shows that factors such as tobacco, diet, infection, alcohol, drugs, and chemicals are more important than genetic (hereditary) factors in determining the development of most cancers. In fact, only 5-10% of all cancer cases can be attributed to genetic defects, whereas the remaining 90-95% have their roots in environment and lifestyle.
BlogBiomarkers are key to understanding dementia risk, disease pathology, and mechanism of action for new therapeutics
Our team was honored to see so many researchers in academic research groups and pharma companies worldwide present findings from clinical trials and research studies spanning various dementia types and utilizing multiple neurological and peripheral matrices using data derived from our SomaScan® Platform. Their discoveries inspire us and are proof that forward momentum is being made – as a consequence to high-throughput proteomics - to better understand this group of diseases and identify meaningful therapuetics .
BlogProteomic profiling for discovery of biomarkers and mechanistic insights into acute myeloid leukemia (AML)
Acute myeloid leukemia (AML) is a cancer of the blood and bone marrow that is characterized by the abnormal proliferation of immature myeloid cells. It is the most common type of leukemia among the adult population that accounts for about 80% of all cases1. AML is a complex, genetically heterogeneous disease, which presents challenges for treatment. Although most patients respond to standard intensive chemotherapy, approximately two-thirds of the patients relapse within 18 months to 5 years of the initial treatment2. The bone marrow microenvironment is thought to play a significant role in mediating the persistence of malignant leukemic stem cells. However, the exact nature of bone marrow–leukemic cell interactions is not well understood.
BlogComplementary proteomic platforms: When adding the SomaScan® Assay to mass spectrometry research makes sense
Pairing the SomaScan Assay with mass spectrometry can help overcome current barriers by measuring thousands of proteins in small volumes of biological samples with low limits of detection, a broad dynamic range, and high reproducibility.
BlogProteomic profiling in cerebrospinal fluid: advancing biomarker discovery in neurology
With nearly 100 million people in the United States alone suffering from a neurologic disease, there is an urgent need for reliable biomarkers to aid in diagnosis, monitoring, and development of new treatments.1,2
BlogProteomic screening of stool samples for Inflammatory Bowel Disease and Colorectal Cancer
Mounting evidence suggests that examining body fluids located near the point of pathology may yield improved biomarkers for disease detection, monitoring, and management.
BlogProteomics and heart failure: improving risk stratification and treatment
Proteomics and heart failure: improving risk stratification and treatment. New research suggests that proteomics could improve – or even replace – current techniques for assessing
BlogPredicting COPD & Emphysema prognosis with biomarkers identified through next-gen proteomics
Chronic obstructive pulmonary diseases, like emphysema, make breathing difficult and may not be properly diagnosed until significant progression has occurred. With proteomics, it is possible
BlogApplying proteomics to one of the world’s longest-running heart studies
Applying proteomics to one of the world’s longest-running heart studies
BlogPlasma proteins reveal molecular signatures of aging and frailty
Plasma proteins reveal molecular signatures of aging and frailty
BlogWhy proteomics?
Proteins are the internet of the human body. Now we have a search engine. Written by Dr. Stephen Williams, Chief Medical Officer of SomaLogic. When
BlogSomaScan® Assay surpasses the “gold standard” in lupus patient stratification
BlogSomaLogic launches tests for NASH
Three years ago, my 36-year-old niece, Sonya, passed away suddenly after complaining of a headache. What killed her was abnormal heart rhythm from undiagnosed nonalcoholic steatohepatitis, or fatty liver disease.
BlogCirculating proteins paint a powerful picture of health
To get a comprehensive picture of health, doctors today must rely on a battery of tests. A recent study suggests that patient-specific patterns in the plasma proteome could provide a single simultaneous and holistic insight into multiple health parameters.